Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease

Published: 2025-06-17 07:40:46 ET VTYX

Published on 06/17/2025 at 07:40